share_log

Weak Statutory Earnings May Not Tell The Whole Story For Winning Health Technology Group (SZSE:300253)

Weak Statutory Earnings May Not Tell The Whole Story For Winning Health Technology Group (SZSE:300253)

疲弱的法定收益可能不能说明赢得健康科技集团(SZSE:300253)的全部故事
Simply Wall St ·  2022/04/30 20:40

A lackluster earnings announcement from Winning Health Technology Group Co., Ltd. (SZSE:300253) last week didn't sink the stock price. However, we believe that investors should be aware of some underlying factors which may be of concern.

一份平淡无奇的财报赢利健康科技集团有限公司。(SZSE:300253)上周股价并未下跌。然而,我们认为投资者应该意识到一些可能令人担忧的潜在因素。

View our latest analysis for Winning Health Technology Group

查看我们赢得健康科技组的最新分析

SZSE:300253 Earnings and Revenue History May 1st 2022
深圳证交所:300253盈利和收入历史2022年5月1日

The Impact Of Unusual Items On Profit

异常项目对利润的影响

To properly understand Winning Health Technology Group's profit results, we need to consider the CN¥145m gain attributed to unusual items. We can't deny that higher profits generally leave us optimistic, but we'd prefer it if the profit were to be sustainable. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. Which is hardly surprising, given the name. We can see that Winning Health Technology Group's positive unusual items were quite significant relative to its profit in the year to March 2022. As a result, we can surmise that the unusual items are making its statutory profit significantly stronger than it would otherwise be.

要正确理解赢利健康科技集团的盈利业绩,我们需要考虑归因于异常项目的1.45亿元人民币收益。我们不能否认,更高的利润通常会让我们保持乐观,但如果利润是可持续的,我们更愿意这样做。当我们分析全球绝大多数上市公司时,我们发现重大的不寻常项目往往不会重复。考虑到这个名字,这并不令人惊讶。我们可以看到,在截至2022年3月的一年中,获奖健康科技集团的积极异常项目与其利润相比相当重要。因此,我们可以推测,这些不寻常的项目使其法定利润比其他情况下要强劲得多。

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

这可能会让你想知道,分析师对未来盈利能力的预测是什么。幸运的是,您可以单击此处查看基于他们估计的未来盈利能力的互动图表。

Our Take On Winning Health Technology Group's Profit Performance

我们对赢得健康科技集团盈利业绩的看法

As previously mentioned, Winning Health Technology Group's large boost from unusual items won't be there indefinitely, so its statutory earnings are probably a poor guide to its underlying profitability. As a result, we think it may well be the case that Winning Health Technology Group's underlying earnings power is lower than its statutory profit. But at least holders can take some solace from the 20% per annum growth in EPS for the last three. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. If you'd like to know more about Winning Health Technology Group as a business, it's important to be aware of any risks it's facing. For example, we've discovered 3 warning signs that you should run your eye over to get a better picture of Winning Health Technology Group.

正如前面提到的,从不寻常的项目中赢得健康科技集团的巨大提振不会无限期地存在,因此该集团的法定收益可能是衡量其潜在盈利能力的糟糕指标。因此,我们认为很可能是赢利健康科技集团的潜在盈利能力低于其法定利润。但至少持有者可以从过去三年每股收益每年20%的增长中得到一些安慰。当然,当谈到分析其收益时,我们只是触及了皮毛;人们还可以考虑利润率、预测增长和投资回报等因素。如果你想了解更多关于赢得健康科技集团的业务,重要的是要意识到它所面临的任何风险。例如,我们发现了3个警告信号,你应该扫视一下,才能更好地了解赢得健康技术组的照片。

This note has only looked at a single factor that sheds light on the nature of Winning Health Technology Group's profit. But there are plenty of other ways to inform your opinion of a company. Some people consider a high return on equity to be a good sign of a quality business. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying to be useful.

这份报告只关注了一个因素,它揭示了赢得健康科技集团利润的本质。但还有很多其他方式可以让你了解一家公司的看法。一些人认为,高股本回报率是高质量企业的良好标志。虽然这可能需要为您做一些研究,但您可能会发现免费拥有高股本回报率的公司的集合,或者是内部人士购买的有用的股票清单。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有什么反馈吗?担心内容吗?保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
这篇由《华尔街日报》撰写的文章本质上是笼统的。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。简单地说,华尔街在提到的任何股票中都没有头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发